A gene-targeted personalized vaccine may delay the return of pancreatic cancer according to a small, but promising, trial. The mRNA vaccine, which was tailored to the genetic makeup of each patient’s tumor, worked in half of those who received it during 18 months of…

Read Full Article (External Site)